Abstract:Jinhui Xu, 1, * Xianglong Chen, 1, * Qian Zhang, 1, * Zhiwei Zhuang, 2 Yunlong Yuan, 3 Lufen Duan, 1 Lu Shi, 1 Chenqi Zhu, 1 JingJing Li, 1 Jian Lu, 4 Yanxia Yu, 1 Lian Tang 1, 5 1 Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 2 Emergency Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 3 Medical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 4 Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 5 Gusu School, Nanjing Medical University, Suzhou, People's Republic of China *These authors contributed equally to this work Correspondence: Lian Tang; Yan-xia Yu, Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, No. 26 Daoqian Street, Gusu District, Suzhou, 215002, People's Republic of China, Tel +86 512 6236 2325, Email ; Purpose: The optimal treatment strategy in patients with hospital-acquired pneumonia (HAP) due to Gram-positive bacteria and renal insufficiency remains challenging. The objective of this study was to compare the outcomes of linezolid versus teicoplanin in HAP patients with renal insufficiency and to explore optimal dosage strategy for linezolid. Methods: The retrospective study enrolled adult patients treated with intravenous linezolid or teicoplanin at Suzhou Municipal Hospital between July 2018 and August 2023. For the comparative pharmacodynamic study, effectiveness, safety and target attainment of trough concentration (C min ) for teicoplanin versus linezolid treatment in HAP patients with document Gram-positive bacteria and renal insufficiency were compared. For the population pharmacokinetics (PPK) analyses, linezolid concentrations collected exclusively from HAP patients with renal insufficiency were used and the optimal dosage strategy was investigated using Monte Carlo simulations. Results: Linezolid-treated patients had a higher bacterial eradication rate than teicoplanin-treated patients (88.5% vs 63.4%, P < 0.001). A higher proportion of patients in the linezolid group experienced at least one adverse reaction (42.0% vs 25.0%, P = 0.025). Significantly more supratherapeutic C min , less therapeutic C min were achieved in the linezolid group (adjusted P < 0.05). A total of 207 linezolid concentrations from 166 patients with renal insufficiency were available for the PPK analysis. Age and creatinine clearance (CrCL) were identified as significant covariates that influenced clearance. Simulations show that 300 mg q12h provide the optimal exposure in patients with a CrCL of 60 or 45 mL/min, and 200 mg q12h was recommended for patients with a CrCL of 30 or 15 mL/min. Conclusion: Linezolid-treated patients with HAP and renal insufficiency had higher bacterial eradication rates, supratherapeutic exposure and adverse reactions than teicoplanin-treated patients. Linezolid dose reduction in patients with renal insufficiency improved the probability of achieving optimal exposure. Keywords: linezolid, population pharmacokinetic, pharmacodynamic, renal insufficiency, hospital-acquired pneumonia Hospital-acquired pneumonia (HAP) is one of the most common healthcare-associated infections, which is associated with increased hospital length of stay, healthcare costs and high mortality. 1,2 Gram-positive bacteria are responsible for a substantial proportion of HAP infections. 3 The isolation of multidrug-resistant Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), has increased steadily in the past decade. 4 Vancomycin, linezolid and teicoplanin are usually the preferred antibiotics for treating HAP caused by multidrug-resistant Gram-positive bacteria. 5–7 The dose-dependent nephrotoxicity of vancomycin has been well recognized, which occurred in up to 40% of patients. 8 Given the risk of nephrotoxicity associated with vancomycin, linezolid and teicoplanin may be considered as preferred alternative choices in patients with renal insufficiency. 9,10 Two randomized clinical trials have already been performed to compare the efficacy and safety outcomes between linezolid and teicoplanin for the treatment -Abstract Truncated-

Pharmacokinetics and Pharmacodynamics of Linezolid in Patients with Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration

A Systematic Review of Linezolid Pharmacokinetics/Pharmacodynamics in Patients Undergoing Continuous Renal Replacement Therapy: Does One Size Fit All?

Dosage Regimen and Toxicity Risk Assessment of Linezolid in Sepsis Patients.

Pharmacokinetic/Pharmacodynamic Parameters of Linezolid in the Epithelial Lining Fluid of Patients with Sepsis

Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients

Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.

Population Pharmacokinetic Model of Linezolid and Probability of Target Attainment in Patients with COVID-19-Associated Acute Respiratory Distress Syndrome on Veno-Venous Extracorporeal Membrane Oxygenation—A Step toward Correct Dosing

Linezolid Pharmacokinetics in Critically Ill Patients: Continuous versus Intermittent Infusion

Developments in the Pharmacokinetic/pharmacodynamic Index of Linezolid: a Step Toward Dose Optimization Using Monte Carlo Simulation in Critically Ill Patients.

The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

Population Pharmacokinetic/Pharmacodynamic Study of Linezolid in Hospital-Acquired Pneumonia Patients with Renal Insufficiency

Effect of the Application of Continuous Cenous Venous Hemofiltration on Pulmonary Vascular Permeability in the Early Stage of Septic Shock

Therapy drug monitoring of linezolid in serum of critically ill patients

Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients

Effect of the Intensity of Continuous Renal Replacement Therapy in Patients with Sepsis and Acute Kidney Injury: a Single-Center Randomized Clinical Trial

Determination of serum linezolid concentration in critically ill patients during continuous veno-venous hemofiltration

Optimizing the dosing regimens of linezolid against gram-positive cocci in critically ill patients with different renal functions: a Monte Carlo simulation

Population Pharmacokinetics and Dosing Regimen Optimization of linezolid in Cerebrospinal Fluid and Plasma of post-operative neurosurgical patients

Linezolid Adsorption on Filters during Continuous Renal Replacement Therapy: An In Vitro Study

Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis